News Releases

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
FUROSCIX® New Drug Application resubmission anticipated in Q3 2021 FREEDOM clinical study on track for topline results in Q3 2021 Ended Q4 with cash, cash equivalents, restricted cash and investments of $105.3 million , sufficient to fund operations through potential FUROSCIX approval and launch,[…]
scPharmaceuticals to Present in Two Upcoming Investor Conferences
BURLINGTON, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA
No additional clinical efficacy, PK or safety data required December 31, 2020 cash, cash equivalents, restricted cash and investments estimated to be $105 million , sufficient to fund operations through potential FUROSCIX® approval and launch and into 2023 BURLINGTON, Mass. , Feb.[…]
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors
BURLINGTON, Mass. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
BURLINGTON, Mass. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]